Stephens Inc. AR Grows Holdings in Amgen Inc. $AMGN

Stephens Inc. AR boosted its position in Amgen Inc. (NASDAQ:AMGN) by 8.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 114,544 shares of the medical research company’s stock after acquiring an additional 9,094 shares during the quarter. Stephens Inc. AR’s holdings in Amgen were worth $40,647,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Hardy Reed LLC increased its position in shares of Amgen by 4.6% during the first quarter. Hardy Reed LLC now owns 681 shares of the medical research company’s stock worth $240,000 after acquiring an additional 30 shares during the last quarter. Argus Investors Counsel Inc. boosted its holdings in Amgen by 46.3% in the first quarter. Argus Investors Counsel Inc. now owns 1,951 shares of the medical research company’s stock valued at $686,000 after purchasing an additional 617 shares during the last quarter. Steigerwald Gordon & Koch Inc. grew its stake in Amgen by 0.4% during the 1st quarter. Steigerwald Gordon & Koch Inc. now owns 70,882 shares of the medical research company’s stock valued at $24,940,000 after purchasing an additional 310 shares in the last quarter. Walkner Condon Financial Advisors LLC increased its holdings in Amgen by 7.8% during the 1st quarter. Walkner Condon Financial Advisors LLC now owns 1,039 shares of the medical research company’s stock worth $366,000 after purchasing an additional 75 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in Amgen during the 1st quarter worth approximately $866,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Canaccord Genuity Group assumed coverage on Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Cantor Fitzgerald restated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research note on Wednesday, April 8th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $400.00 price target on shares of Amgen in a report on Wednesday. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Finally, Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $355.50.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $374.15 on Monday. The company’s fifty day moving average is $342.43 and its two-hundred day moving average is $348.09. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The stock has a market capitalization of $201.93 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 3.68 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business posted $4.90 EPS. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.39 EPS for the current year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.